BLOG

After Kymera’s raise, Nurix nabs $120M as it too hones in on clinical work

Sanofi- and Gilead Sciences-backed Nurix Therapeutics is following suit with rival biotech Kymera in raising a major cash haul for its protein modulation R&D work. Nurix has grabbed $120 million to push on with its drug discovery platform that focuses on manipulating the ubiquitin system, which breaks down damaged or unneeded proteins.

Back to the Blog .st0{stroke:#000;stroke-width:3}.st0,.st1{fill:none}